Research programme: semi-synthetic compounds - Floratek Pharma
Latest Information Update: 13 Mar 2023
At a glance
- Originator Floratek Pharma
- Class Antineoplastics; Polyphenols
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Neurodegenerative disorders
Most Recent Events
- 13 Mar 2023 Preclinical trials in Cancer in Switzerland (unspecified route) before March 2023 (Floratek Pharma website, March 2023)
- 13 Mar 2023 Preclinical trials in Neurodegenerative disorders in Switzerland (unspecified route) before March 2023 (Floratek Pharma website, March 2023)
- 13 Mar 2023 Floratek Pharma plans clinical trials (Floratek Pharma website, March 2023)